Department of Biology, University of Louisville Speed School of Engineering, Louisville, Kentucky, USA.
Department of Chemical Engineering, University of Louisville Speed School of Engineering, Louisville, Kentucky, USA.
AAPS J. 2021 May 10;23(3):66. doi: 10.1208/s12248-021-00602-z.
Bacterial vaginosis (BV) is one of the most common vaginal infections that affects hundreds of millions of women of reproductive age, worldwide. Traditional treatment strategies, such as oral and topical antibiotics, have shown efficacy against BV, but frequent recurrence of infection and the development of antibiotic-resistant bacteria remain as significant challenges. Alternatively, recent progress in understanding immune, microbiological, and metabolic interactions in the vaginal microbiota has prompted the consideration of administering probiotic organisms to restore and maintain vaginal health within the context of BV prevention and treatment. Given this, the objective of this review is to discuss existing and potential alternative approaches to deliver, and to potentially sustain the delivery of probiotics, to prevent and/or treat BV infections. First, a brief overview is provided regarding the probiotic species and combinatorial probiotic strategies that have shown promise in the treatment of BV and in restoring female reproductive health. Additionally, the advantages and challenges associated with current oral and intravaginal probiotic delivery platforms are discussed. Lastly, we present emerging and promising alternative dosage forms, such as electrospun fibers and 3D bioprinted scaffolds, that may be adapted as new strategies to intravaginally deliver probiotic organisms. Graphical abstract.
细菌性阴道病(BV)是一种最常见的阴道感染,影响着全球数以亿计的育龄妇女。传统的治疗策略,如口服和局部抗生素,已显示出对 BV 的疗效,但感染的频繁复发和抗生素耐药菌的发展仍然是重大挑战。相反,最近在理解阴道微生物群中的免疫、微生物和代谢相互作用方面的进展促使人们考虑使用益生菌来恢复和维持阴道健康,以预防和/或治疗 BV 感染。有鉴于此,本综述的目的是讨论现有的和潜在的替代方法来输送,并有可能维持益生菌的输送,以预防和/或治疗 BV 感染。首先,简要概述了在治疗 BV 和恢复女性生殖健康方面显示出前景的益生菌种类和组合益生菌策略。此外,还讨论了当前口服和阴道内益生菌输送平台的优点和挑战。最后,我们提出了新兴的有前途的替代剂型,如静电纺丝纤维和 3D 生物打印支架,这些剂型可能被改编为阴道内输送益生菌的新策略。